Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
PharmaMar
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age \>/= 18 years
Confirmed diagnosis of unresectable epithelial ovarian, fallopian tube or primary peritoneal cancer.
Platinum-resistant disease (PFI: 1-6 months after last platinum-containing chemotherapy).
Evaluable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 criteria
No more than three prior systemic chemotherapy regimens
Eastern Cooperative Oncology Group (ECOG) performance status (PS) (ECOG PS) ≤ 2
Adequate hematological, renal, metabolic and hepatic function
You may not be if
Concomitant diseases/conditions: cardiac disease, immunodeficiency, chronic active hepatitis or cirrhosis, uncontrolled infection, bowel obstruction, any other major illness
Prior treatment with PM01183, trabectedin, or with both PLD and topotecan.
Requirement of permanent or frequent (i.e., once per week) external drainages within two weeks prior to randomization
Clareo Health | Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients
